Sector Watch: Healthcare - Oct 03 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $121.26 +0.89 0.74% | XBI: $94.90 +1.70 1.82% | Updated Oct 03, 2018 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| VTGN VistaGen Therapeutics $54.0M |
2.09+0.57 10.0 M 50.5x |
38% | ||
| TRVN52WH Trevena $264.0M |
3.47+0.81 14.5 M 5.8x |
30% | ||
| AMRN52WH Amarin $6.0B |
18.20+2.24 38.7 M 2.1x |
14% | ||
| OMED OncoMed Pharmaceuticals $93.2M |
2.42+0.29 73.6 K |
14% | ||
| NBRV Nabriva Therapeutics AG $180.8M |
3.06+0.34 1.1 M 2.3x |
13% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| BLFS BioLife Solutions $248.5M |
13.89-2.62 865.0 K 2.3x |
-16% | ||
| ASMB Assembly Biosciences $812.8M |
31.94-3.82 445.3 K 2.5x |
-11% | ||
| CYH Community Health Systems $313.9M |
2.70-0.26 4.7 M 2.3x |
-9% | ||
| CATB Catabasis Pharmaceuticals $55.2M |
0.78-0.07 3.0 M 2.2x |
-9% | ||
| ARWR Arrowhead Pharmaceuticals $1.6B |
18.56-1.14 1.8 M |
-6% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain [globenewswire.com]Assembly Biosciences Announces Oral Presentation at 2018 AASLD [globenewswire.com]
Community Health Systems Completes Divestiture of Oklahoma City Hospital | Business Wire [businesswire.com]
BioLife Solutions Reports Record Third Quarter 2018 Preliminary Revenue of $5.3 Million, up 79% Year-over-Year [prnewswire.com]
Trevena announces completion of leadership transition and appointment of new director [globenewswire.com]
Colorectal Cancer - Pipeline Review, H1 2018 - ResearchAndMarkets.com | Business Wire [businesswire.com]
Global Post-Operative Pain Pipeline Review, H2 2018 - Therapeutic Assessment of 40 Companies - ResearchAndMarkets.com | Business Wire [businesswire.com]
Amarin to Present at the Cantor Global Healthcare Conference Nasdaq:AMRN [globenewswire.com]
Health Management Associates Pays $260 Million To Settle Whistleblower Lawsuits | Business Wire [businesswire.com]
Global Settlement Resolves U.S. Department of Justice Investigation Into Health Management Associates, Inc. and Related Affiliates | Business Wire [businesswire.com]
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy | Business Wire [businesswire.com]
Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences | Business Wire [businesswire.com]
Consolidated Research: 2018 Summary Expectations for Community Health, Aradigm, Avnet, Sanchez Energy, Black Stone Minerals, and Navient ? Fundamental Analysis, Key Performance Indications [globenewswire.com]
SSM Partners Completes Minority Investment In ProviderTrust [prnewswire.com]
Thinking about buying stock in Amarin Corporation, Facebook, General Electric, Netflix or Pandora? [prnewswire.com]
OncoMed to Present at the Cantor Global Healthcare Conference [globenewswire.com]
Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics | Business Wire [businesswire.com]
REDUCE-IT? Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint [globenewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
